US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued Patient Access to TECELRA

Reuters

2025/08/05

US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued <a href="https://laohu8.com/S/PASO">Patient Access</a> to TECELRA

US WorldMeds (USWM) has successfully completed the acquisition of Adaptimmune Therapeutics plc's cell-therapy assets. The acquisition, initially announced on July 28, 2025, includes TECELRA®, lete-cel, afami-cel, and uza-cel. USWM paid $55 million in cash at closing and may provide up to an additional $30 million in performance-based milestone payments. TECELRA, a genetically modified T cell immunotherapy for synovial sarcoma, will remain available to patients without interruption. USWM also plans to bring lete-cel to the U.S. market, with potential regulatory approval expected in 2026, and will continue developing uza-cel in collaboration with Galapagos. Approximately half of Adaptimmune's U.S.-based workforce will join USWM to support these efforts. Adaptimmune will offer transition services until June 2026 to ensure operational continuity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43551) on August 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557348339"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557348339\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557348339?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557348339","market":"fut","top_or_hot":-1,"title":"US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued Patient Access to TECELRA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued <a href=\"https://laohu8.com/S/PASO\">Patient Access</a> to TECELRA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        US WorldMeds (USWM) has successfully completed the acquisition of <a href=\"https://laohu8.com/S/ADAP\">Adaptimmune Therapeutics plc</a>'s cell-therapy assets. The acquisition, initially announced on July 28, 2025, includes TECELRA®, lete-cel, afami-cel, and uza-cel. USWM paid $55 million in cash at closing and may provide up to an additional $30 million in performance-based milestone payments. TECELRA, a genetically modified T cell immunotherapy for synovial sarcoma, will remain available to patients without interruption. USWM also plans to bring lete-cel to the U.S. market, with potential regulatory approval expected in 2026, and will continue developing uza-cel in collaboration with Galapagos. Approximately half of Adaptimmune's U.S.-based workforce will join USWM to support these efforts. Adaptimmune will offer transition services until June 2026 to ensure operational continuity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43551) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued Patient Access to TECELRA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued Patient Access to TECELRA\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-05 04:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued <a href=\"https://laohu8.com/S/PASO\">Patient Access</a> to TECELRA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        US WorldMeds (USWM) has successfully completed the acquisition of <a href=\"https://laohu8.com/S/ADAP\">Adaptimmune Therapeutics plc</a>'s cell-therapy assets. The acquisition, initially announced on July 28, 2025, includes TECELRA®, lete-cel, afami-cel, and uza-cel. USWM paid $55 million in cash at closing and may provide up to an additional $30 million in performance-based milestone payments. TECELRA, a genetically modified T cell immunotherapy for synovial sarcoma, will remain available to patients without interruption. USWM also plans to bring lete-cel to the U.S. market, with potential regulatory approval expected in 2026, and will continue developing uza-cel in collaboration with Galapagos. Approximately half of Adaptimmune's U.S.-based workforce will join USWM to support these efforts. Adaptimmune will offer transition services until June 2026 to ensure operational continuity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43551) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL5Md6tw:1","article_id":"2557348339","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557348339","pubTimestamp":1754337627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"US WorldMeds  has successfully completed the acquisition of Adaptimmune Therapeutics plc's cell-therapy assets. The acquisition, initially announced on July 28, 2025, includes TECELRA, lete-cel, afami-cel, and uza-cel. USWM paid $55 million in cash at closing and may provide up to an additional $30 million in performance-based milestone payments. TECELRA, a genetically modified T cell immunotherapy for synovial sarcoma, will remain available to patients without interruption. USWM also plans to bring lete-cel to the U.S. market, with potential regulatory approval expected in 2026, and will continue developing uza-cel in collaboration with Galapagos. Approximately half of Adaptimmune's U.S.-based workforce will join USWM to support these efforts. Adaptimmune will offer transition services until June 2026 to ensure operational continuity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SUPN":"Supernus Pharmaceuticals","BK4139":"生物科技"},"translate_title":"美国WorldMeds完成对Adaptimmune细胞治疗产品组合的收购，确保患者持续获得TECELRA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAP":0.9,"SUPN":0.9},"content_text":"US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued Patient Access to TECELRA\n    \n\n        US WorldMeds (USWM) has successfully completed the acquisition of Adaptimmune Therapeutics plc's cell-therapy assets. The acquisition, initially announced on July 28, 2025, includes TECELRA®, lete-cel, afami-cel, and uza-cel. USWM paid $55 million in cash at closing and may provide up to an additional $30 million in performance-based milestone payments. TECELRA, a genetically modified T cell immunotherapy for synovial sarcoma, will remain available to patients without interruption. USWM also plans to bring lete-cel to the U.S. market, with potential regulatory approval expected in 2026, and will continue developing uza-cel in collaboration with Galapagos. Approximately half of Adaptimmune's U.S.-based workforce will join USWM to support these efforts. Adaptimmune will offer transition services until June 2026 to ensure operational continuity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43551) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}